Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Review Article
Authors: Paolacci, Luciaa; 1 | Giannandrea, Davidb; c; 1 | Mecocci, Patriziaa; * | Parnetti, Lucillab
Affiliations: [a] Department of Medicine, Section of Gerontologyand Geriatrics, University of Perugia, Perugia, Italy | [b] Department of Medicine, Section of Neurology, Center for Memory Disturbances-Lab of Clinical Neurochemistry, University of Perugia, Perugia, Italy | [c] Neurology Unit, Presidio Ospedaliero Alto Chiascio, USL 1 Umbria, Italy
Correspondence: [*] Correspondence to: Prof. Patrizia Mecocci, MD, PhD, Section of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Piazzale Gambuli, 1, 06132 Perugia, Italy. Tel.: +39 075 5783270; Fax: +39 075 5783878; E-mail: [email protected].
Note: [1] These authors contributed equally to this work.
Abstract: In recent years, many efforts have been spent to identify sensitive biomarkers able to improve the accuracy of Alzheimer’s disease (AD) diagnosis. Two different workgroups (NIA-AA and IWG) included cerebrospinal fluid (CSF) and neuroimaging findings in their sets of criteria in order to improve diagnostic accuracy as well as early diagnosis. The number of subjects with cognitive impairment increases with aging but the oldest old (≥85 years of age), the fastest growing age group, is still the most unknown from a biological point of view. For this reason, the aim of our narrative mini-review is to evaluate the pertinence of the new criteria for AD diagnosis in the oldest old. Moreover, since different subgroups of oldest old have been described in scientific literature (escapers, delayers, survivors), we want to outline the clinical profile of the oldest old who could really benefit from the use of biomarkers for early diagnosis. Reviewing the literature on biomarkers included in the diagnostic criteria, we did not find a high degree of evidence for their use in the oldest old, although CSF biomarkers seem to be still the most useful for excluding AD diagnosis in the “fit” subgroup of oldest old subjects, due to the high negative predictive value maintained in this age group.
Keywords: Aging, Alzheimer’s disease, biomarker, cerebrospinal fluid, MRI, oldest-old, PET
DOI: 10.3233/JAD-161127
Journal: Journal of Alzheimer's Disease, vol. 58, no. 2, pp. 323-335, 2017
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]